Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M10,961Revenue $M4,003Net Margin (%)7.5Z-Score3.8
Enterprise Value $M12,182EPS $-0.1Operating Margin %10.9F-Score7
P/E(ttm))33.4Cash Flow Per Share $4.7Pre-tax Margin (%)8.9Higher ROA y-yY
Price/Book3.310-y EBITDA Growth Rate %-8.7Quick Ratio1.3Cash flow > EarningsY
Price/Sales2.55-y EBITDA Growth Rate %-28.0Current Ratio2.4Lower Leverage y-yY
Price/Cash Flow6.8y-y EBITDA Growth Rate %270ROA % (ttm)5.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)10.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M169ROI % (ttm)-1.9Gross Margin Increase y-yY

Gurus Latest Trades with HSP

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HSPJoel Greenblatt 2014-09-30 Buy 0.16%$49.59 - $56.21
($53.12)
$ 64.7822%New holding, 313242 sh.313,242
HSPMario Gabelli 2014-09-30 Add0.01%$49.59 - $56.21
($53.12)
$ 64.7822%Add 24.71%254,870
HSPJohn Rogers 2014-09-30 Reduce-0.45%$49.59 - $56.21
($53.12)
$ 64.7822%Reduce -22.28%2,433,369
HSPMario Gabelli 2014-06-30 Add0.01%$42.14 - $52.41
($47.4)
$ 64.7837%Add 32.91%204,370
HSPJohn Rogers 2014-06-30 Reduce-0.53%$42.14 - $52.41
($47.4)
$ 64.7837%Reduce -24.15%3,130,809
HSPVanguard Health Care Fund 2014-03-31 Add0.18%$40.89 - $45
($42.83)
$ 64.7851%Add 22.69%8,375,170
HSPMario Gabelli 2014-03-31 Add0.01%$40.89 - $45
($42.84)
$ 64.7851%Add 30.68%153,770
HSPRichard Snow 2014-03-31 Sold Out -1.3%$40.89 - $45
($42.84)
$ 64.7851%Sold Out0
HSPBrian Rogers 2014-03-31 Sold Out -0.37%$40.89 - $45
($42.84)
$ 64.7851%Sold Out0
HSPJohn Rogers 2014-03-31 Reduce-0.28%$40.89 - $45
($42.84)
$ 64.7851%Reduce -11.62%4,127,850
HSPJohn Rogers 2013-12-31 Add0.12%$38.53 - $42.19
($40.25)
$ 64.7861%Add 5.28%4,670,630
HSPRichard Snow 2013-09-30 Reduce-0.85%$38.45 - $42.03
($39.88)
$ 64.7862%Reduce -36.89%811,590
HSPRichard Pzena 2013-09-30 Sold Out -0.27%$38.45 - $42.03
($39.88)
$ 64.7862%Sold Out0
HSPJohn Rogers 2013-09-30 Reduce-0.23%$38.45 - $42.03
($39.88)
$ 64.7862%Reduce -7.79%4,436,305
HSPJohn Rogers 2013-06-30 Add0.34%$30.57 - $38.31
($33.81)
$ 64.7892%Add 12.97%4,811,105
HSPBrian Rogers 2013-06-30 Add0.24%$30.57 - $38.31
($33.81)
$ 64.7892%Add 135.3%2,750,000
HSPRichard Snow 2013-06-30 Reduce-0.27%$30.57 - $38.31
($33.81)
$ 64.7892%Reduce -11.68%1,286,067
HSPMichael Price 2013-03-31 Add0.65%$28.96 - $35.99
($32.42)
$ 64.78100%Add 61.62%400,000
HSPVanguard Health Care Fund 2013-03-31 Add0.62%$28.96 - $35.99
($32.42)
$ 64.78100%Add 242.15%6,826,070
HSPJohn Rogers 2013-03-31 Add0.6%$28.96 - $35.99
($32.42)
$ 64.78100%Add 33.12%4,258,620
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HSP is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
HSP Joel Greenblatt 2014-09-30313,2420.190.16New Buy
HSP Mario Gabelli 2014-09-30254,8700.150.07+24.71%
HSP Michael Price 2014-09-30400,0000.242.6
HSP Robert Bruce 2014-09-3010,0000.010.14
HSP Vanguard Health Care Fund 2014-09-308,375,1704.951.1
HSP John Rogers 2014-09-302,433,3691.441.6-22.28%
HSP Meridian Funds 2013-06-30257,4000.150.37+8.42%
Premium Most recent portfolio changes are included for Premium Members only!


HSP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Werner Thomas ESVP, Finance & CFO 2015-01-15Sell10,000$61.565.23view
Stober Matthew RSVP, Operations 2015-01-12Sell2,000$61.84.82view
Werner Thomas ESVP, Finance & CFO 2014-12-15Sell10,000$60.866.44view
Hoffman Richard JCVP, Controller & CAO 2014-12-02Sell21,850$60.327.39view
SOKOLOV JACQUE JDirector 2014-11-28Sell7,547$60.327.39view
Yoskowitz Marc JSVP, Strategy & Corporate Dev 2014-11-25Sell11,523$59.938.09view
Meyers Kenneth FSVP, Chief Human Resources Ofr 2014-11-24Sell46,250$59.668.58view
SMITH BRIAN JSVP and Special Counsel 2014-11-24Sell185,700$59.319.22view
Bedward RoyceSVP, General Counsel and Sec'y 2014-11-20Sell2,333$58.6710.41view
Werner Thomas ESVP, Finance & CFO 2014-11-17Sell10,000$57.7312.21view

Press Releases about HSP :

    Quarterly/Annual Reports about HSP:

    News about HSP:

    Articles On GuruFocus.com
    Feeling Good With This Med Company Jan 20 2015 
    Weekly Insider Sells Highlight: REGN, HSP, TYC, AAPL Nov 30 2014 
    Weekly CFO Sells Highlight: Hospira Inc, Rockwood Holdings Inc, Mylan Inc. Nov 30 2014 
    Jeff Auxier Second Quarter Shareholder Letter Aug 08 2014 
    Brian Rogers' T. Rowe Price Equity Income Fund Semi-Annual Report 2013 Dec 02 2013 
    Ariel Capital's John Rogers Trims Sotheby’s, DeVry, Hospira, IPG, Others Nov 18 2013 
    Five Companies Cut - Pzena Investment Management Update Nov 12 2013 
    John Rogers Comments on Hospira Inc. Jul 25 2013 
    Rowe Price Equity Income Fund Buys Apple, Carnival, Joy Global, Sells Thermo Fisher, Energizer, SLM Jul 19 2013 
    John Rogers Ariel Fund Second Quarterly Commentary Jul 18 2013 

    More From Other Websites
    Hospira to Host Conference Call for Fourth-Quarter 2014 Results and 2015 Projections Jan 29 2015
    Hospira to Host Conference Call for Fourth-Quarter 2014 Results and 2015 Projections Jan 29 2015
    Hospira's Plum 36O Infusion System Gets FDA Clearance - Analyst Blog Jan 21 2015
    Feeling Good With This Med Company Jan 20 2015
    Hospira Receives FDA Clearance for Plum 360™ Infusion System Jan 20 2015
    Hospira Receives FDA Clearance for Plum 360™ Infusion System Jan 20 2015
    Hospira Submits Retacrit Regulatory Application to the FDA - Analyst Blog Jan 16 2015
    Hospira Inc. (HSP): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Jan 15 2015
    Hospira Submits New Biologics License Application to U.S. FDA for Proposed Epoetin Alfa Biosimilar Jan 14 2015
    HOSPIRA INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Material... Jan 13 2015
    HOSPIRA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 12 2015
    Hospira Submits New Biologics License Application to U.S. FDA for Proposed Epoetin Alfa Biosimilar Jan 12 2015
    Hospira Statement On FDA Advisory Committee's Recommendation To Approve The First U.S. Biosimilar Jan 11 2015
    HOSPIRA STATEMENT ON FDA ADVISORY COMMITTEE’S RECOMMENDATION TO APPROVE THE FIRST U.S. BIOSIMILAR Jan 11 2015
    Hospira Announces Significant Progess On Global Device Strategy Jan 08 2015
    HOSPIRA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 08 2015
    Hospira Announces Significant Progess On Global Device Strategy Jan 08 2015
    Hospira's non-opioid painkiller gets FDA approval Dec 30 2014
    Hospira's injectable painkiller gets FDA approval Dec 30 2014
    Hospira Receives U.S. FDA Approval of Proprietary Analgesic Dyloject™(diclofenac sodium) Injection Dec 30 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK